Want to see BHST full AI Analyst Report?
BHST Stock Chart & Stats
$2.00
$0.11(5.73%)
At close: 4:00 PM EDT
$2.00
$0.11(5.73%)
Day’s Range― - ―
52-Week Range$1.37 - $12.80
Previous Close$2.03
Volume137.38K
Average Volume (3M)29.20K
Market Cap
$37.63M
Enterprise Value$66.16M
Total Cash (Recent Filing)$16.22M
Total Debt (Recent Filing)$17.55M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Nov 30, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding22,667,843
10 Day Avg. Volume24,682
30 Day Avg. Volume29,204
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)3.75
Price to Sales (P/S)2.77
P/FCF Ratio-9.97
Enterprise Value/Market Cap1.76
Enterprise Value/Revenue1.86
Enterprise Value/Gross Profit3.16
Enterprise Value/Ebitda-9.07
Forecast
1Y Price Target
$9.00Price Target Upside350.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$42.89M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginsRapid revenue expansion alongside a gross margin near 59% indicates strong unit economics and growing commercial traction. If sustained, this combination can provide increasing gross-profit resources for product development, platform investment, and eventual operating leverage as the business scales.
CDMO Platform CommercializationThe first major CDMO supply agreement validates the botanical synthesis platform beyond the VINIA consumer product and creates a pathway toward recurring manufacturing revenue. Its scale could diversify the business, deepen customer relationships, and improve long-term operating leverage as capacity expands.
Improved Liquidity PositionThe substantial year-over-year increase in cash and deposits strengthens the company’s ability to fund research, commercial development, and CDMO capacity without immediately relying on equity issuance. Greater liquidity also provides more time to convert platform opportunities into revenue and cash generation.
Bears Say
Persistent Losses And Cash BurnDespite strong gross margins, BHST remains materially unprofitable and consumes cash in operations and investment. Continued negative cash generation can limit funding flexibility, increase dependence on financing or existing reserves, and delay the point at which revenue growth translates into durable shareholder value.
Lowered 2026 OutlookThe reduced revenue outlook signals weaker near-term execution or demand than previously expected, while the wider EBITDA loss range indicates that growth investments are not yet producing operating leverage. This raises the risk that profitability and self-funded expansion remain further out.
Rising Debt And Weak ReturnsHigher debt combined with deeply negative returns constrains financial flexibility while the company is still loss-making. Leverage can absorb more cash through financing costs or repayment needs, leaving fewer resources for platform development and increasing execution pressure during the scale-up period.
BioHarvest Sciences News
BHST FAQ
What was BioHarvest Sciences’s price range in the past 12 months?
BioHarvest Sciences lowest stock price was $1.37 and its highest was $12.80 in the past 12 months.
What is BioHarvest Sciences’s market cap?
BioHarvest Sciences’s market cap is $37.63M.
When is BioHarvest Sciences’s upcoming earnings report date?
BioHarvest Sciences’s upcoming earnings report date is Nov 30, 2026 which is in 49 days.
How were BioHarvest Sciences’s earnings last quarter?
BioHarvest Sciences released its earnings results on Aug 11, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.118 by -$0.052.
Is BioHarvest Sciences overvalued?
According to Wall Street analysts BioHarvest Sciences’s price is currently Undervalued.
Does BioHarvest Sciences pay dividends?
BioHarvest Sciences does not currently pay dividends.
What is BioHarvest Sciences’s EPS estimate?
BioHarvest Sciences’s EPS estimate is -0.14.
How many shares outstanding does BioHarvest Sciences have?
BioHarvest Sciences has 22,667,843 shares outstanding.
What happened to BioHarvest Sciences’s price movement after its last earnings report?
BioHarvest Sciences reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.118. Following the earnings report the stock price went down -1.19%.
Which hedge fund is a major shareholder of BioHarvest Sciences?
Currently, no hedge funds are holding shares in BHST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioHarvest Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (350.00% Upside)
$9.00 (350.00% Upside)
Blogger Sentiment
Bullish
BHST Sentiment 67%
Sector Average 63%
Sector Average 63%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.20%
12-Months-Change
Fundamentals
Return on Equity
-58.30%
Trailing 12-Months
Asset Growth
60.33%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
BioHarvest Sciences
BioHarvest Sciences Inc. is a biotechnology company that operates through two segments: Products and CDMO Services. The company has developed a botanical synthesis platform technology to grow plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, and sale of science-based health and wellness nutraceutical solutions, as well as offering Contract Development and Manufacturing Operation (CDMO) services to third parties in the pharmaceutical, cosmeceutical, and nutrition industries.
BHST Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced significant strategic progress and validation—most notably the major fragrance CDMO contract, stronger cash position, and government-backed technology grants—against near-term revenue guidance cuts, higher operating expenses, and continued adjusted EBITDA losses. Management is pivoting resources toward higher-margin CDMO opportunities and capacity build-out, accepting lower near-term product revenue (VINIA) in order to pursue longer-term profitability and scale. Key positives are the sizeable contract pipeline and material cash increase; key negatives are reduced 2026 top-line guidance and short-term profitability pressures stemming from reallocated marketing and development spend.View all BHST earnings summariesBHST Stock 12 Month Forecast
Average Price Target
$9.00
▲(350.00% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.05% Mutual Funds
6.82% Other Institutional Investors
93.12% Public Companies and
Individual Investors